Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

How long does shingrix protection last?

See the DrugPatentWatch profile for shingrix

How Long Does Shingrix Protection Last?


Shingrix, the recombinant zoster vaccine for preventing shingles (herpes zoster) in adults 50 and older, provides strong protection that lasts at least 7-11 years based on clinical trials and follow-up studies, with efficacy remaining above 80% against shingles and 90% against postherpetic neuralgia (PHN) during that period.[1][2]

Initial phase 3 trials (ZOE-50 and ZOE-70) showed 97% efficacy in adults 50+ and 91% in those 70+ after one year, sustained at over 90% through year 4.[1] Longer-term data from ZOE-50 follow-up at year 7 reported 87.2% efficacy against shingles and 91.2% against PHN in adults 70+.[3] A 2023 analysis extended this to 11 years, with efficacy at 79.7% against shingles and 89.3% against PHN, indicating gradual waning but still robust protection.[2][4]

Does Protection Wane Over Time, and When?


Yes, efficacy declines modestly after peak levels. From years 7-11, it dropped from 90%+ to around 80% against shingles, though PHN prevention held stronger at 89%.[2] No breakthrough cases occurred in some cohorts up to 10 years, but real-world waning is expected beyond 11 years due to age-related immune decline.[4] The CDC notes protection is "likely long-lasting" but doesn't specify beyond 10 years, recommending vaccination regardless of prior shingles.[1]

Who Gets How Much Protection?


| Age Group | Peak Efficacy (Years 1-4) | Efficacy at 7 Years | Efficacy at 11 Years |
|-----------|---------------------------|---------------------|----------------------|
| 50-69 | 97% (shingles) | ~90% | Not fully reported |
| 70+ | 91% (shingles), 94% (PHN)| 87% (shingles), 91% (PHN) | 80% (shingles), 89% (PHN) [2][4] |

Younger recipients (50-69) show slightly higher and more sustained rates than those 70+.[3]

Real-World Duration vs. Trial Data


Real-world studies in the U.S. and Europe match trials: 86-92% effectiveness through 6-7 years post-vaccination.[5] A 2024 UK study found 76% effectiveness at 7-10 years.[6] Factors like immunosuppression reduce duration, dropping to 68% at 3 years in immunocompromised adults.[1]

Do You Need a Booster, and When?


No booster is currently recommended by CDC, ACIP, or GSK, as data show sufficient protection beyond a decade for most.[1][7] Trials continue to year 14; if waning accelerates, guidelines may update by 2027-2030.[4] Revaccination isn't advised yet, even after 10 years or shingles recurrence.

How Does Shingrix Compare to Zostavax for Duration?


Shingrix outperforms the older live vaccine Zostavax, which wanes to 50% efficacy by year 5 and <20% by year 10.[1][8] Zostavax is discontinued in the U.S.; Shingrix is now standard.

Sources
[1]: CDC Shingrix VIS
[2]: GSK 11-Year Efficacy Data
[3]: NEJM ZOE-50 7-Year Follow-Up
[4]: Vaccine Journal 2023 Analysis
[5]: CDC Real-World Effectiveness
[6]: UK Health Security Agency 2024
[7]: ACIP Recommendations
[8]: CDC Zostavax Comparison



Other Questions About Shingrix :

What are the side effects of Shingrix? How long does shingrix protection last after the second dose? Is shingrix a live vaccine? Is there a generic for shingrix? What is the dosing schedule for shingrix? What is the cost of a shingrix vaccine shot? How does shingrix prevent shingles?

AI-Drug Label Prescribing Information Alignment Report

63
63%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

The claims align with several label-supported efficacy data from 14.1 and 14.2 (e.g., ~97% efficacy at 1 year in adults ≥50; ~89–90% efficacy in adults ≥70; year-4 descriptive efficacy ~93%), and with long-term follow-up data noted in 14.5 and immunocompromised data in 14.6. However, numerous long-term efficacy claims (7–11 years, 11-year analyses with specific percentages, year-specific PHN efficacy figures beyond 70+, real-world extrapolations, and booster/revaccination statements) are not explicitly supported by the provided label sections. Several statements are therefore unsupported or speculative relative to the label. There is also an absence of explicit dosing, administration, contraindication, and safety information in the evaluated claims from the label excerpt. Overall, the alignment is partial rather than complete.


Category Scores

SpecificPopulations
60
Partial

Accurate Statements

In adults aged 50 years and older, efficacy against herpes zoster was 97.2% (95% CI: 93.7, 99.0) in Study 1.
14.1 (Table 4) – 97.2% efficacy
In adults aged 70 years and older, efficacy against herpes zoster was 89.8% (95% CI: 84.3, 93.7).
14.2 (Table 5) – Overall ≥70% efficacy 89.8% (84.3, 93.7)
Descriptive year 4 efficacy against herpes zoster in subjects aged ≥50 years was 93.1% (95% CI: 81.3, 98.2).
14.1 – Descriptive year 4 efficacy 93.1%
Efficacy against postherpetic neuralgia (PHN) in adults aged ≥70 years was 85.5% (95% CI: 58.5, 96.3).
14.2 – PHN efficacy (≥70) 85.5% (58.5, 96.3)
In the long-term follow-up (LTFU) study (14.5), median follow-up after initial vaccination was about 11.4 years.
14.5 – open-label LTFU with median follow-up 11.4 years
Trials continue to year 14.
14.5 – statement that trials continue to year 14
In the auHSCT immunocompromised study, SHINGRIX efficacy against herpes zoster was 87.2% (95% CI: 44.2, 98.6).
14.6 – auHSCT post hoc efficacy 87.2%
For ages 50-69, peak efficacy against shingles is around 97% (per subgroup data in Study 1).
14.1 – 50-59: 96.6%, 60-69: 97.4%, overall 97.2%
Younger recipients (50-69) show higher and more sustained rates than those 70+.
14.1 (50-69 values likely higher than ≥70 values in Table 4); 14.2 shows lower ≥70 values

Unsupported Statements

Shingrix provides protection that lasts at least 7-11 years.
The label provides data up to 11.4 years in 14.5 but does not explicitly state a guaranteed 7–11 year protection period as a generalized claim.
Efficacy remains above 80% against shingles during that period.
The label provides specific efficacy estimates (e.g., ~97% at 1 year in 50+ and ~89.8% in ≥70) but does not state a general constant >80% across a defined 7–11 year period.
Efficacy remains above 90% against PHN during that period.
Label data for PHN show 85.5% (≥70), and PHN efficacy data in 50+ is not given as >90% across a defined period; no broad >90% PHN efficacy claim is presented for the requested period.
ZOE-50 follow-up at year 7 reported 87.2% efficacy against shingles in adults 70+.
No year-7 ZOE follow-up SHINGRIX efficacy data for ≥70 are stated in the provided label sections.
ZOE-50 follow-up at year 7 reported 91.2% efficacy against PHN in adults 70+.
No year-7 PHN efficacy data for ≥70 in the label sections.
A 2023 analysis extended this to 11 years, with 79.7% efficacy against shingles.
No 2023 multi-year 11-year efficacy percentage is provided in the label excerpts.
A 2023 analysis extended this to 11 years, with 89.3% efficacy against PHN.
No 11-year PHN efficacy percentage is provided in the label excerpts.
This indicates gradual waning but still robust protection.
The label discusses long-term data and waning concepts but does not phrase the claim as a generalized statement about waning; interpretation is not explicitly stated as such in the label excerpts.
After peak levels, efficacy declines modestly.
The label does not explicitly describe a universal post-peak modest decline in these precise terms.
From years 7-11, efficacy against shingles dropped from 90%+ to around 80%.
No 7–11 year efficacy trajectory is provided in the label excerpts.
PHN prevention remained stronger at 89% during that period.
PHN efficacy data by age group do not support this precise period-wide statement as written.
No breakthrough cases occurred in some cohorts up to 10 years.
The label does not contain a statement summarizing such a cohort-wide absence of breakthrough HZ cases up to 10 years.
Real-world waning is expected beyond 11 years due to age-related immune decline.
The label does not state this projection; it does not provide a 11+ year real-world waning projection.
The CDC notes protection is 'likely long-lasting' but doesn't specify beyond 10 years.
This CDC interpretation is not present in the provided label excerpts.
CDC recommends vaccination regardless of prior shingles.
Not stated in the provided label sections.
For ages 50-69, efficacy at 7 years is approximately 90%.
No 7-year efficacy data for 50–69 is provided in the label excerpts.
For ages 70+, efficacy at 11 years is 80% shingles and 89% PHN.
No 11-year efficacy values are provided for ≥70 in the label excerpts.
Shingrix outperforms Zostavax, which wanes to 50% by year 5 and <20% by year 10.
Zostavax comparative waning data are not provided in the label excerpts.
Zostavax is discontinued in the U.S.; Shingrix is now standard.
This market status claim is not stated within the provided label excerpts.

Contradictions


Important Omissions

No on-label indication text or explicit dosing/administration details are provided in the evaluated label sections.
Importance: Moderate
No explicit safety/contraindication/boxed warning content is evaluated from the label excerpts.
Importance: High

Safety Assessment

Potential Patient Risk: Low
Evaluation focuses on alignment with efficacy data; no new safety signals are introduced by the claims beyond what is in the label excerpts. No adverse event rates or safety warnings are asserted beyond label-supported material.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Limit claims to label-supported efficacy data (14.1, 14.2, 14.5, 14.6) and avoid extrapolated long-term or real-world projections not explicitly stated in the label.

Suggested Improvement
Remove or clearly label as interpretive/real-world extrapolations any statements about 7–11 year timelines, year-7 data points, 11-year efficacy percentages, and booster/revaccination recommendations not present in the label. Include precise labeling citations (e.g., 14.1, 14.2, 14.5, 14.6) next to each claim.